Continuous renal replacement therapy with regional citrate anticoagulation: Do we really know the details?

Current Opinion in Anaesthesiology

Volumn 26, Issue 4, 2013, Pages 428-437

  Lanckohr, Christian ^a   Hahnenkamp, Klaus ^a   Boschin, Matthias ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

acute kidney injury; continuous renal replacement therapy; dialysis; regional citrate anticoagulation

Indexed keywords

CITRATE CALCIUM; CITRATE SODIUM; CREATININE; CYSTATIN C; DIALYSIS FLUID; HEPARIN; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; PRISMOCITRAT; TRINATRIUMCITRATE; UNCLASSIFIED DRUG; UREA; UREMIC TOXIN;

ACUTE KIDNEY FAILURE; ANTICOAGULANT THERAPY; CLINICAL PRACTICE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIALYSATE; EFFLUENT; EVIDENCE BASED PRACTICE; FLOW RATE; HUMAN; INTENSIVE CARE UNIT; MEMBRANE FILTER; METABOLIC DISORDER; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGIONAL CITRATE ANTICOAGULATION; REVIEW; RISK ASSESSMENT; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANTICOAGULANTS; CITRIC ACID; HUMANS; INTENSIVE CARE; RENAL REPLACEMENT THERAPY;

EID: 84880827290     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3283620224     Document Type: Review

References (65)

1. Siew ED, Deger SM. Recent advances in acute kidney injury epidemiology. Curr Opin Nephrol Hypertens 2012; 21:309-317.
2. Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81:819-825.
3. Ostermann M, Chang R. Correlation between the AKI classification and outcome. Crit Care 2008; 12:R144.
4. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813-818. (Pubitemid 41175724)
5. Vaara ST, Pettila V, Reinikainen M, et al. Population-based incidence, mortality and quality of life in critically ill patients treated with renal replacement therapy: a nationwide retrospective cohort study in finnish intensive care units. Crit Care 2012; 16:R13.
6. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442-448.
7. Cohen SD, Kimmel PL. Long-term sequelae of acute kidney injury in the ICU. Curr Opin Crit Care 2012; 18:623-628.
8. Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol 2012; 23:979-984.
9. GramsME, Rabb H. The distant organ effects of acute kidney injury. Kidney Int 2012; 81:942-948.
10. Yap SC, Lee HT. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology 2012; 116:1139-1148.
11. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure -definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
12. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
13. Valette X, du Cheyron D. A critical appraisal of the accuracy of the RIFLE and AKIN classifications in defining 'acute kidney insufficiency' in critically ill patients. J Crit Care 2013; 28:116-125.
14. Acute Kidney Injury Work Group. KDIGO cinical practice guideline for acute kidney injury. Kidney Int 2012; 2:1-138.
15. Friedrich JO, Wald R, Bagshaw SM, et al. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care 2012; 16:R146.
16. Wald R, Friedrich JO, Bagshaw SM, et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI): a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. Crit Care 2012; 16:R205.
17. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007; 33:1563-1570. (Pubitemid 47312485)
18. Legrand M, Darmon M, Joannidis M, et al. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med 2013; 39:101-108.
19. Vanholder R, Van Biesen W, Hoste E, et al. Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish? Crit Care 2011; 15:204.
20. Schwenger V, Weigand MA, Hoffmann O, et al. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury: a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012; 16:R140.
21. Karvellas CJ, Farhat MR, Sajjad I, et al. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care 2011; 15:R72.
22. Elseviers MM, Lins RL, Van der Niepen P, et al. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. Crit Care 2010; 14:R221.
23. Btaiche IF, Mohammad RA, Alaniz C, et al. Amino acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy. Pharmacotherapy 2008; 28:600-613. (Pubitemid 351620029)
24. Joannidis M, Forni LG. Clinical review: timing of renal replacement therapy. Crit Care 2011; 15:223.
25. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258-1270.
26. Hakim RM, Breyer J, Ismail N, et al. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661-669. (Pubitemid 24138419)
27. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305-310. (Pubitemid 34438837)
28. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:179-184.
29. Claure-Del Granado R, Macedo E, Chertow GM, et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol 2011; 6:467-475.
30. Negash DT, Dhingra VK, Copland M, et al. Intensity of continuous renal replacement therapy in acute kidney injury in the intensive care unit: a systematic review and meta-analysis. Vasc Endovascular Surg 2011; 45: 504-510.
31. Prowle JR, Schneider A, Bellomo R. Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care 2011; 15:207.
32. Van Wert R, Friedrich JO, Scales DC, et al. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med 2010; 38:1360-1369.
33. Honore PM, Jacobs R, Boer W, et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 2012; 33:44-51.
34. Rimmele T, Kellum JA. High-volume hemofiltration in the intensive care unit: a blood purification therapy. Anesthesiology 2012; 116:1377-1387.
35. Tolwani A, Wille KM. Advances in continuous renal replacement therapy: citrate anticoagulation update. Blood Purif 2012; 34:88-93.
36. Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 2012; 16:249.
37. Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59:810-818.
38. Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38:20-28.
39. Meier-Kriesche HU, Gitomer J, Finkel K, et al. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29:748-752. (Pubitemid 32299711)
40. Bakker AJ, Boerma EC, Keidel H, et al. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med 2006; 44:962-966. (Pubitemid 44155864)
41. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31:2450-2455. (Pubitemid 37281728)
42. Saner FH, Treckmann JW, Geis A, et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring postoperative renal replacement therapy. Nephrol Dial Transplant 2012; 27:1651-1657.
43. Balik M, Zakharchenko M, Leden P, et al. Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration -a comparison between 2 citrate modalities and unfractionated heparin. J Crit Care 2013; 28:87-95.
44. Balik M, Zakharchenko M, Otahal M, et al. Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy. Blood Purif 2012; 33:80-87.
45. Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy -heparin or citrate? Crit Care 2011; 15:202.
46. Weinberg JM, Venkatachalam MA, Roeser NF, et al. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci U S A 2000; 97:2826-2831. (Pubitemid 30159256)
47. Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30:260-265. (Pubitemid 38253417)
48. Kutsogiannis DJ, Gibney RT, Stollery D, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67:2361-2367. (Pubitemid 41623398)
49. Morgera S, Haase M, Ruckert M, et al. Regional citrate anticoagulation in continuous hemodialysis -acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 2005; 101:c211-c219.
50. Tolwani AJ, Prendergast MB, Speer RR, et al. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006; 1:79-87.
51. Nurmohamed SA, Vervloet MG, Girbes AR, et al. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif 2007; 25:316-323. (Pubitemid 47450565)
52. Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37:2018-2024.
53. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545-552.
54. Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26:232-239.
55. Shum HP, Chan KC, Yan WW. Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution. Ther Apher Dial 2012; 16:81-86.
56. Mariano F, Morselli M, Bergamo D, et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011; 26: 3882-3888.
57. Link A, Klingele M, Speer T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care 2012; 16:R97.
58. Claure-Del Granado R, Macedo E, Chertow GM, et al. Toward the optimal dose metric in continuous renal replacement therapy. Int J Artif Organs 2012; 35:413-424.
59. Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012; 16:R111.
60. Schultheiss C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012; 16:R162.
61. Davenport A, Gardner C, Delaney M, et al. The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010; 25: 897-901.
62. Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 2006; 70:1312-1317. (Pubitemid 44435183)
63. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40:1523-1528.
64. Seyler L, Cotton F, Taccone FS, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15:R137.
65. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease -a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:1122-1137.